<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268255</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000447160</org_study_id>
    <secondary_id>WSU-D-2820</secondary_id>
    <secondary_id>WSU-HIC-100304M1F</secondary_id>
    <secondary_id>ZENECA-1839US/0258</secondary_id>
    <nct_id>NCT00268255</nct_id>
  </id_info>
  <brief_title>Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Study of Induction Gefitinib and Concurrent Radiotherapy in Patients With Previously Untreated, Medically Inoperable Stage I or II Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Gefitinib may make tumor cells more sensitive to radiation therapy. Giving gefitinib together&#xD;
      with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation&#xD;
      therapy when given together with gefitinib and to see how well they work in treating patients&#xD;
      with inoperable stage I or stage II non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity profile and maximum tolerated dose of radiotherapy when given in&#xD;
           combination with gefitinib in patients with previously untreated, medically inoperable&#xD;
           stage I or II non-small cell lung cancer. (Phase I)&#xD;
&#xD;
        -  Determine the efficacy of gefitinib when given for 6 weeks prior to and concurrent with&#xD;
           radiotherapy, in terms of objective response rate (partial and complete response), in&#xD;
           these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the 3-month tumor response (complete and partial response) in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the 6-week response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the local disease control rate (complete and partial response, stable disease)&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the local progression-free survival and disease-specific survival (cancer vs&#xD;
           co-morbid disease) of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the pattern of failure (e.g., local, regional, or distant metastasis) in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the acute and late radiation toxic effects to organs at risk in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the safety profile of gefitinib in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study of radiotherapy.&#xD;
&#xD;
        -  Patients receive oral gefitinib once daily for 13 weeks. Patients also undergo&#xD;
           radiotherapy 5 days a week for 7 weeks beginning at week 7. Patients continue to receive&#xD;
           gefitinib alone after completion of radiotherapy in the absence of disease progression&#xD;
           or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6-10 patients receive escalating doses of radiotherapy until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6&#xD;
      patients experience acute dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive oral gefitinib as in phase I and radiotherapy at the MTD&#xD;
           determined in phase I. After the completion of radiotherapy, patients continue to&#xD;
           receive gefitinib in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 37 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never moved forward with accrual.&#xD;
  </why_stopped>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enzyme inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>protein tyrosine kinase inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiosensitization</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Any non-small cell histology allowed&#xD;
&#xD;
          -  T1-3, N0* disease&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Refused or ineligible for surgery&#xD;
&#xD;
          -  Measurable disease, defined as lesion diameter ≤ 5 cm NOTE: *No evidence of N1 or N2&#xD;
             disease by positron emission tomography (PET) scan or any histological means&#xD;
             (mediastinoscopy, thoracotomy, transbronchial, tracheal aspirations, or&#xD;
             transesophageal aspiration by endoscopic ultrasound guidance&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Any performance status&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No restrictions&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No restrictions&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ CTC grade 2&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
          -  Chronic, stable, asymptomatic radiographic changes allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception&#xD;
&#xD;
          -  No known severe hypersensitivity to gefitinib or any of the excipients of this product&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No uncontrolled systemic disease&#xD;
&#xD;
          -  No psychiatric illness or other severe medical condition that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the chest or mediastinum&#xD;
&#xD;
          -  No concurrent elective nodal irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No concurrent ophthalmic surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all other prior anticancer therapy (alopecia allowed)&#xD;
&#xD;
          -  More than 30 days since prior nonapproved or investigational agents&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers, including any of the following:&#xD;
&#xD;
          -  Phenytoin&#xD;
&#xD;
          -  Carbamazepine&#xD;
&#xD;
          -  Barbiturates&#xD;
&#xD;
          -  Rifampin&#xD;
&#xD;
          -  Phenobarbital&#xD;
&#xD;
          -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent systemic retinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew T. Turrisi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>April 12, 2013</last_update_submitted>
  <last_update_submitted_qc>April 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

